A Summary of the Pneumococcal Vaccines Market Development (2023 to 2033)

The global pneumococcal vaccines market is projected to have an average-paced CAGR of 4.1% during the forecast period. The current valuation of the market is US$ 8.9 Billion in 2023. The market value of the pneumococcal vaccines market is anticipated to surpass a market valuation of US$ 13.3 Billion by 2033. A historical market valuation of US$ 8.5 Billion has been recorded by the analysts of Future Market Insights for the concerned market during the base year.

Growth is supported by:

  • Surging awareness amongst the global population in regard to immunization programs for pneumonia is likely to aid market growth.
  • An increase in government support to educate people about being vaccinated against the occurrence of pneumonia is estimated to reshape the market landscape through 2033.
  • The rise in the prevalence of pneumococcal contaminations within the growing population is identified as a key cause behind the industry expansion.
  • The introduction of novel vaccines for the prevention of pneumococcal diseases is the major driving factor of the pneumococcal vaccines industry.
  • The rising prevalence of bloodstream infection, bacteremic pneumonia, meningitis, middle ear infection, and bacteremia is a key growth propellant of the market.
Report Attribute Details
Pneumococcal Vaccines Market Value (2023) US$ 8.9 Billion
Pneumococcal Vaccines Market Anticipated Value (2033) US$ 13.3 Billion
Pneumococcal Vaccines Projected Growth Rate (2023 to 2033) 4.1%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Stretched Timelines to Manufacture Pneumococcal Vaccines Limits Market Growth

Although the market is estimated to have favorable growth through the forecast period, it is identified that certain factors prevailing in the market are likely to curb the demand for pneumococcal vaccines in the forthcoming years.

It is witnessed that the manufacturing or production process of pneumococcal vaccines requires a longer timeline, which acts as a key restraining element in the market expansion. Additionally, there is a very high cost associated with the development of pneumococcal vaccines. Therefore, it is expected that the aforementioned factors are likely to hinder the propulsion of industry through the forecast period.

Manufacture of Protein-based Vaccines Narrows Immunization Gaps Amidst People Across Developing Economies

The industry players are diversifying their product portfolios with the launch of protein-based vaccines. The introduction of protein-based vaccines is creating several growth opportunities in the market to further expand and upscale the prominence of pneumococcal vaccines.

Protein-based vaccines have inexpensive production procedures that further aid the market’s prominence. Additionally, these products have logistical and protocol advantages, along with the inclusion of stability at a broad range of temperatures.

These vaccines are identified to narrow the immunization gaps that prevail among the middle-class and abundant populace across developing economies. Therefore, it is estimated that the pneumococcal vaccines market is likely to accrue significant shares through the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

PCV in Infant Routine Immunization in 2023 Excel Against the Historical Market Scenario

It is identified that the pneumococcal vaccines market is witnessing an unprecedented surge in the recent few years. There has been an approximate rise of US$ 0.4 Billion from the base year to the current. This growth in market valuation can be highly attributed to the rising number of young children under 2 to 5 years possessing a high risk of pneumococcal diseases.

The rising geriatric population has also made a significant contribution to the industry growth of pneumococcal vaccines. Severe complications and contagiousness of diseases in old adults have fostered the growth of the pneumococcal vaccines market during the period 2018 to 2022.

The market advanced at a moderate pace of 3.2% CAGR and accounted for a market value of US$ 8.5 Billion in the base year. It is identified that the rise in the number of diabetes patients, smokers, heavy drinkers, and individuals having chronic health conditions, who are vulnerable to ailments and infections owing to their weak immune systems is estimated to further fuel demand through the foreseen years.

Additionally, a key factor making a significant contribution to the market growth is the introduction of the Pneumococcal Conjugate Vaccine (PCV) by government agencies across emerging countries in infant routine immunization. This factor is expected to further trail growth through the projection period.

Historical CAGR (2018 to 2022) 3.2%
Market Value in 2022 US$ 8.5 Billion
Forecast CAGR (2023 to 2033) 4.1%
Market Value in 2023 US$ 8.9 Million

Category-wise Insights

Dominant Market Segments Expand as a result of the Introduction Of New Products and the Rise In Health Concerns.

Prevenar-13 - By Product Type

It is identified that the Prevenar-13 segment by product type category is likely to trail at a significant rate through the forecast period. In the base year, this segment was advancing forward at a CAGR of 3.2% and is likely to hold dominant shares in the pneumococcal vaccines market through 2033.

This segment is projected to account for a revenue share of US$ 9,500 Million in 2023. The growing prominence of Prevenar 13 can be attributed to the inclusion of thirteen pneumococcus and serotypes. The hospital sector is giving this vaccine to patients due to the presence of serotypes 6A and 19A.

The Centers for Disease Control and Prevention (CDC) has also made recommendations for Prevenar-13 for adults, who are above the age of 65 years. Therefore, this segment is likely to accrue significant shares of the market through 2033.

Public Authorities - By Distribution Channel

After an in-depth analysis of the market, it is witnessed that the public authorities segment by distribution channel category is likely to hold dominant shares in the pneumococcal vaccines market. In 2022, this segment trailed at a CAGR of 6.8% and is likely to move forward at a notable pace, registering a CAGR of 5% during the period 2023 to 2033.

Public health agencies and community clinics are accounting for the largest market share owing to the large number of vaccine purchases made by organizations such as GAVI, WHO, UNICEF, and others. These organizations make bulk purchases of pneumonia vaccines and distribute them across diver geographies for social causes.

The hospital segment is also estimated to have grown at a significant rate and is projected to surpass a market valuation of US$ 12,400 Million by the end of 2023.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Insights

Regional Market Shares in the Pneumococcal Vaccines Market

Region North America
Country United States of America
CAGR (2023 to 2033) 1.8%
Region Europe
Country United Kingdom
CAGR (2023 to 2033) 2.5%
Region Europe
Country Germany
CAGR (2023 to 2033) 2.9%
Region Asia Pacific
Country China
CAGR (2023 to 2033) 9.0%
Region Asia Pacific
Country India
CAGR (2023 to 2033) 9.2%

Introduction of Awareness Programs Across Diverse Countries Promote Industry Growth of Pneumococcal Vaccines

Country United States of America
Statistics The USA is estimated to hold the highest share of the pneumococcal vaccines market through the projection period. The pneumococcal vaccines industry in the USA is advancing at a CAGR of 1.8%. the market is estimated to surpass a valuation of US$ 4.9 Billion by the end of 2033. Approximate Growth in Market Value: US$ 825.6 Million
Historical CAGR: 0.4%
Growth Propellants A well-established healthcare infrastructure across the North American region serving a large number of patients is estimated to foster the growth of the pneumococcal market in the upcoming years. It is identified that the 5-7% mortality rate in the USA is due to pneumococcal diseases. The rapid growth in the geriatric population is also a key factor fueling the market expansion of pneumococcal vaccines.
Country Germany
Statistics Germany is likely to hold a significant share of the pneumococcal vaccines market in the European region. The pneumococcal vaccines industry in the UK is advancing at a CAGR of 2.9%. The market is estimated to surpass a valuation of US$ 191.9 Million by the end of 2033. Approximate Growth in Market Value: US$ 47.2 Million
Historical CAGR: 2.1%
Growth Propellants The high prevalence and invasion of pneumonia across the people of Europe which accounted for approximately 15.08% of 1,00,000 people is a key cause fueling the market size of pneumococcal vaccines in Germany. A growing number of research and development activities and clinical trials aided by government advances in the country is reshaping the industry landscape in 2023.
Country China
Statistics The pneumococcal vaccines market in China is estimated to move forward at a substantial rate, slating a CAGR of 9.0% through the forecast period. The market is estimated to surpass a valuation of US$ 2.9 Billion by the end of 2033. Approximate Growth in Market Value: US$ 1.7 Billion
Historical CAGR: 35.3%
Growth Propellants The medical healthcare sector across China is witnessing a rise in investment from government authorities. Medical institutes across China are heavily using pneumococcal vaccines for treating diseases like meningitis, blood-stream infection, and more. Therefore, it is estimated to emerge as one of the most significant and remunerative markets in the pneumococcal vaccine landscape.

Start-up Ecosystem

Attempts of New Entrants Penetrate Remunerative Market Scopes

The new entrants in the pneumococcal vaccines market are leveraging advancements in technology to launch new products and gain a competitive advantage. These firms are continually investing in research and development activities to keep themselves in tandem with the changing consumer preferences and end-use industry demands. Efforts are being made to strengthen their foothold in the market and aid the further progression of the pneumococcal vaccines market.

Top 2 Start-ups to Watch For

Affinivax - This firm is a clinical-stage biopharmaceutical organization, who are having a next-generation technology platform for vaccines known as the multiple antigen presentation systems. This firm is likely to penetrate the market and be in tandem with the demand from the hospital sector through the forecast period.

GPN Vaccine - This is an Australian start-up firm that is offering vaccines for pneumonia. The startup sterilizes its proprietary, engineered, and avirulent strain of S. pneumonia with gamma rays to produce Gamma-PNTM, a whole-cell vaccine. The vaccine induces broad-spectrum immunity against the antigens of the pneumococcus bacterium and is effective against different pathogenic pneumococcal strains.

Competitive Landscape

Key Industry Players Cede A Silver Lining to the Pneumonia Vaccines Market With Their Technology Innovations

The pneumococcal vaccines market is highly fragmented and the key manufacturers are deploying several organic and inorganic growth strategies to compete with the existing players in the market. The biggies are heavily investing in research and development activities to leverage advancements to the attributes of pneumococcal vaccines. They are making attempts for treating the chronic diseases prevailing amongst the geriatric population and others in an effective manner.

Activirosomes is developing vaccines for viral infections. The company is leveraging active virosome technology for the generation of non-replicating derivates of measles and some other comprehensive viruses. The virosome-based vaccines are carrying only the viral genes that are necessary for eliciting an immune response.

Recent Developments

  • In September 2020, a Japanese pharmaceutical company, Shinogi, made an announcement to enter into a license agreement with Hanavax, a next-generation nasal vaccine manufacturer. The agreement was likely to assist the company in research and development activities, commercialization, manufacturing, and distribution of Streptococcus pneumonia vaccines developed by Hanavax.
  • In December 2019, China-based biotechnology company, Walvax Biotechnology Co., Ltd. received approval from the regulatory body of China, the National Medical Products Administration for its pneumococcal-13 valent conjugate vaccine. This vaccine is also estimated to act as an alternative to Prevnar-13 for immunizing children in the age group of 6 months to 5 years.
  • In January 2018, Pfizer, one of the global leaders in the pharmaceutical industry made an announcement to reduce the price of the PCV-13 4-dose vial vaccine from US$ 3.05 to US$ 2.95 per dosage in the Gavi-supported countries.

Some of the key players proliferating in the market are:

  • Astellas Pharma Inc
  • GlaxoSmithKline Plc
  • Merck & Co. Inc
  • Panacea Biotech Ltd
  • Pfizer Inc
  • Sanofi S.A
  • Walvax Biotechnology Co. Ltd
  • CSL Ltd
  • Serum Institute of India Pvt. Ltd
  • Talley Group Ltd

Key Segments in the Pneumococcal Vaccines Market

By Product Type:

  • Pneumococcal Polysaccharide Vaccines
  • Pneumococcal Conjugate Vaccines

By Distribution Channel:

  • Pharmacies
  • Community Clinics
  • Public Health Agencies
  • Others

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • Middle East and Africa (MEA)
  • Europe

Frequently Asked Questions

What is the Growth Outlook for the Pneumococcal Vaccines Market?

The growth outlook for the market is predicted to advance at a CAGR of 4.1% from 2023 to 2033.

Which Region Leads the Pneumococcal Vaccines Market?

The North American region is anticipated to lead the market during the forecast period.

What is the market valuation of Pneumococcal Vaccines in 2023?

The market valuation of the market stands at US$ 8.9 Billion in 2023.

How much Growth Potential does the Pneumococcal Vaccines Market hold?

The market is likely to hold a valuation of US$ 13.3 Billion by 2033.

Which sector is the key driver in the Pneumococcal Vaccines Market?

The healthcare industry sector is the key driver in the market.

Table of Content

1. Executive Summary | Pneumococcal Vaccines Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2017 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033

        5.3.1. Synflorix

        5.3.2. Prevenar-13

        5.3.3. PCV 13 (Pipeline)

        5.3.4. V114 (Merck)

        5.3.5. PCV-20 (Pfizer)

        5.3.6. PCV-10 (SII)

        5.3.7. PPSV- 23

    5.4. Y-o-Y Growth Trend Analysis By Product Type, 2017 to 2022

    5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033

6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channels

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channels, 2017 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channels, 2023 to 2033

        6.3.1. Wholesaler (Pharmacy channel)

        6.3.2. Specialized Companies

        6.3.3. Public Authorities

        6.3.4. Others

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channels, 2017 to 2022

    6.5. Absolute $ Opportunity Analysis By Distribution Channels, 2023 to 2033

7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Sector

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Sector, 2017 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Sector, 2023 to 2033

        7.3.1. Public

        7.3.2. Private

    7.4. Y-o-Y Growth Trend Analysis By Sector, 2017 to 2022

    7.5. Absolute $ Opportunity Analysis By Sector, 2023 to 2033

8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Europe

        8.3.3. Asia Pacific

        8.3.4. Latin America

        8.3.5. Rest of the World

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. United States of America

            9.2.1.2. Canada

        9.2.2. By Product Type

        9.2.3. By Distribution Channels

        9.2.4. By Sector

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Product Type

        9.3.3. By Distribution Channels

        9.3.4. By Sector

    9.4. Key Takeaways

10. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. United Kingdom

            10.2.1.2. Germany

            10.2.1.3. Spain

            10.2.1.4. France

            10.2.1.5. Italy

            10.2.1.6. Belgium

            10.2.1.7. Rest of Europe

        10.2.2. By Product Type

        10.2.3. By Distribution Channels

        10.2.4. By Sector

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Product Type

        10.3.3. By Distribution Channels

        10.3.4. By Sector

    10.4. Key Takeaways

11. Asia Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. India

            11.2.1.4. Australia

            11.2.1.5. New Zealand

            11.2.1.6. Rest of Asia Pacific

        11.2.2. By Product Type

        11.2.3. By Distribution Channels

        11.2.4. By Sector

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Product Type

        11.3.3. By Distribution Channels

        11.3.4. By Sector

    11.4. Key Takeaways

12. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Brazil

            12.2.1.2. Mexico

            12.2.1.3. Rest of Latin America

        12.2.2. By Product Type

        12.2.3. By Distribution Channels

        12.2.4. By Sector

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Product Type

        12.3.3. By Distribution Channels

        12.3.4. By Sector

    12.4. Key Takeaways

13. Rest of the World Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Rest of the World

        13.2.2. By Product Type

        13.2.3. By Distribution Channels

        13.2.4. By Sector

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Product Type

        13.3.3. By Distribution Channels

        13.3.4. By Sector

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. United States of America

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Product Type

            14.1.2.2. By Distribution Channels

            14.1.2.3. By Sector

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Product Type

            14.2.2.2. By Distribution Channels

            14.2.2.3. By Sector

    14.3. United Kingdom

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Product Type

            14.3.2.2. By Distribution Channels

            14.3.2.3. By Sector

    14.4. Germany

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Product Type

            14.4.2.2. By Distribution Channels

            14.4.2.3. By Sector

    14.5. Spain

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Product Type

            14.5.2.2. By Distribution Channels

            14.5.2.3. By Sector

    14.6. France

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Product Type

            14.6.2.2. By Distribution Channels

            14.6.2.3. By Sector

    14.7. Italy

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Product Type

            14.7.2.2. By Distribution Channels

            14.7.2.3. By Sector

    14.8. Belgium

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Product Type

            14.8.2.2. By Distribution Channels

            14.8.2.3. By Sector

    14.9. China

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Product Type

            14.9.2.2. By Distribution Channels

            14.9.2.3. By Sector

    14.10. Japan

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Product Type

            14.10.2.2. By Distribution Channels

            14.10.2.3. By Sector

    14.11. India

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Product Type

            14.11.2.2. By Distribution Channels

            14.11.2.3. By Sector

    14.12. Australia

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Product Type

            14.12.2.2. By Distribution Channels

            14.12.2.3. By Sector

    14.13. New Zealand

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Product Type

            14.13.2.2. By Distribution Channels

            14.13.2.3. By Sector

    14.14. Brazil

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Product Type

            14.14.2.2. By Distribution Channels

            14.14.2.3. By Sector

    14.15. Mexico

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Product Type

            14.15.2.2. By Distribution Channels

            14.15.2.3. By Sector

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Product Type

        15.3.3. By Distribution Channels

        15.3.4. By Sector

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Glaxosmithkline plc.

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. LG Chem Ltd.

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Merck & Co., Inc.

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Panacea Biotec Limited

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Pfizer Inc.

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Pnuvax Incorporated

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Serum Institute of India Pvt. Ltd.

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Shenzhen Kangtai Biological Products Co., Ltd.

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. SK Bioscience

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Walvax Biotechnology Co., Ltd.

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Recommendations

Healthcare

Pneumonia Diagnostics Market

October 2022

REP-GB-2970

276 pages

Healthcare

Pneumococcal Testing Market

June 2022

REP-GB-11289

287 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Pneumococcal Vaccines Market

Schedule a Call